FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Moore, K
  • Oza, A
  • Colombo, N
  • Oaknin, A
  • Scambia, G
  • Lorusso, D
  • Farias-Eisner, R
  • Banerjee, S
  • Murphy, C
  • Tanyi, J
  • Hirte, Holger
  • Konner, J
  • Lim, P
  • Hayes, M Prasad
  • Monk, B
  • Kim, S
  • Wang, J
  • Pautier, P
  • Vergote, I
  • Birrer, M

publication date

  • October 1, 2019